Geron (GERN) vs Immix Biopharma (IMMX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immix Biopharma (IMMX) has outperformed Geron (GERN) over the past year, gaining 265.7% versus a loss of 11.6%. Geron is the larger company by market cap ($783.8 million vs $770.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GERN | IMMX |
|---|---|---|
| Share price | $1.22 | $9.29 |
| Market cap | $783.82M | $770.17M |
| 1-day change | +1.67% | -2.11% |
| YTD return | -7.58% | +77.63% |
| 1-year return | -11.59% | +265.75% |
| 5-year return | -14.89% | — |
| Forward P/E | 30.50 | — |
| EPS (TTM) | $-0.11 | $-0.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.01 | $15.10 |
| 52-week low | $1.04 | $2.31 |
| Distance from 52-week high | -39.30% | -38.48% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +248.36% | +161.57% |
| Average volume | 10.09M | 1.65M |
| Shares outstanding | 642.47M | 82.90M |
| Employees | 258 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMX has outperformed GERN by 277.3 percentage points over the past year.
About Geron
GERN stock →Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
About Immix Biopharma
IMMX stock →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
GERN vs IMMX FAQ
Which is bigger, Geron or Immix Biopharma?
Geron (GERN) is larger, with a market capitalization of $783.82M compared with $770.17M for Immix Biopharma (IMMX).
Which stock has performed better over the past year, GERN or IMMX?
IMMX returned +265.75% over the past 12 months, compared with -11.59% for GERN (price return, excluding dividends). Past performance does not predict future results.
Are Geron and Immix Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.